Global and United States Sustained-release Medicine Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and United States Sustained-release Medicine Market Report & Forecast 2024-2034
Sustained-release Medicine refer to preparations that can be continuously released for a long time after administration to achieve long-acting effects, and the drug release is mainly a first-order rate process. Controlled release preparations (controlled release preparations) refer to the preparations that can automatically release the drug at a predetermined speed within a predetermined time, so that the blood drug concentration can be kept constant within the effective concentration range for a long time.
Since there is no difference between sustained-release preparations and controlled-release preparations in the some countries, so, in this report, Extended release (ER), Sustained release (SR), Controlled release (CR) and Delayed release (D
Market Analysis and InsightsGlobal and United States Sustained-release Medicine Market
This report focuses on global and United States Sustained-release Medicine market, also covers the segmentation data of other regions in regional level and county level.
The global Sustained-release Medicine revenue was US$ 34850 million in 2024 and is forecast to a readjusted size of US$ 55040 million by 2034 with a CAGR of 6.9% during the review period (2024-2034).
The main global manufacturers of sustained-release drugs are Sanofi, Novartis, Bayer, Johnson & Johnson, Takeda, AstraZeneca, AbbVie, etc. The top seven manufacturers occupy a total market share of nearly 35%, of which the largest manufacturer is Sanofi, with a market share of 10.85%. Global sustained-release drug production regions are mainly located in Europe, the United States, China, etc., of which the top two regions occupy more than 65% of the market share. In terms of their product categories, original ground medicine have a higher market share of 63.96%, while generics have a lower share.
Global Sustained-release Medicine Scope and Market Size
Sustained-release Medicine market is segmented in regional and country level, by players, by Type and by Distribution Channel. Companies, stakeholders, and other participants in the global Sustained-release Medicine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Distribution Channel for the period 2018-2034.
For United States market, this report focuses on the Sustained-release Medicine market size by players, by Type and by Distribution Channel, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.
Sanofi
Novartis
Bayer
Johnson & Johnson
Takeda
AstraZeneca
AbbVie
Pfizer
Collegium Pharmaceutical, Inc
Endo Pharmaceuticals
Shanghai Shyndec Pharmaceutical
Zhuhai Rundu Pharmaceutical
China Res Double-Crane
Segment by Type
Original Ground Medicine
Generic Medicine
Segment by Distribution Channel
Hospital
Drugstore
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Sustained-release Medicine definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by distribution channel, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Sustained-release Medicine companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Sustained-release Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by distribution channel and by country revenue for each segment.
Chapter 7EMEA by type, by distribution channel and by region, revenue for each segment.
Chapter 8China by type, by distribution channel revenue for each segment.
Chapter 9APAC (excluding China) by type, by distribution channel and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sustained-release Medicine revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
Since there is no difference between sustained-release preparations and controlled-release preparations in the some countries, so, in this report, Extended release (ER), Sustained release (SR), Controlled release (CR) and Delayed release (D
Market Analysis and InsightsGlobal and United States Sustained-release Medicine Market
This report focuses on global and United States Sustained-release Medicine market, also covers the segmentation data of other regions in regional level and county level.
The global Sustained-release Medicine revenue was US$ 34850 million in 2024 and is forecast to a readjusted size of US$ 55040 million by 2034 with a CAGR of 6.9% during the review period (2024-2034).
The main global manufacturers of sustained-release drugs are Sanofi, Novartis, Bayer, Johnson & Johnson, Takeda, AstraZeneca, AbbVie, etc. The top seven manufacturers occupy a total market share of nearly 35%, of which the largest manufacturer is Sanofi, with a market share of 10.85%. Global sustained-release drug production regions are mainly located in Europe, the United States, China, etc., of which the top two regions occupy more than 65% of the market share. In terms of their product categories, original ground medicine have a higher market share of 63.96%, while generics have a lower share.
Global Sustained-release Medicine Scope and Market Size
Sustained-release Medicine market is segmented in regional and country level, by players, by Type and by Distribution Channel. Companies, stakeholders, and other participants in the global Sustained-release Medicine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Distribution Channel for the period 2018-2034.
For United States market, this report focuses on the Sustained-release Medicine market size by players, by Type and by Distribution Channel, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.
By Company
Sanofi
Novartis
Bayer
Johnson & Johnson
Takeda
AstraZeneca
AbbVie
Pfizer
Collegium Pharmaceutical, Inc
Endo Pharmaceuticals
Shanghai Shyndec Pharmaceutical
Zhuhai Rundu Pharmaceutical
China Res Double-Crane
Segment by Type
Original Ground Medicine
Generic Medicine
Segment by Distribution Channel
Hospital
Drugstore
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Sustained-release Medicine definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by distribution channel, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Sustained-release Medicine companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Sustained-release Medicine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by distribution channel and by country revenue for each segment.
Chapter 7EMEA by type, by distribution channel and by region, revenue for each segment.
Chapter 8China by type, by distribution channel revenue for each segment.
Chapter 9APAC (excluding China) by type, by distribution channel and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Sustained-release Medicine revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices